WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205541

CAS#: 1239908-20-3 (citrate)

Description: MLN9708, also known as ixazomib citrate, is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN9708, compared with bortezomib, has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinical studies.

Price and Availability


USD 150
USD 650
USD 3250

USD 250
USD 950
USD 4250

USD 450
USD 1650
USD 6250

MLN9708 purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 205541
Name: MLN9708
CAS#: 1239908-20-3 (citrate)
Chemical Formula: C20H23BCl2N2O9
Exact Mass: 516.08737
Molecular Weight: 517.12162
Elemental Analysis: C, 46.45; H, 4.48; B, 2.09; Cl, 13.71; N, 5.42; O, 27.85

Related CAS #: 1072833-77-2   1239908-20-3 (citrate)   1201902-80-8    

Synonym: MLN9708; MLN-9708; MLN 9708; ixazomib citrate. MMLN-2238-prodrug. Ixazomib-prodrug; Ninlaro.

IUPAC/Chemical Name: 4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid


InChi Code: InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1

SMILES Code: O=C(C(C1)(CC(O)=O)OB([C@@H](NC(CNC(C2=CC(Cl)=CC=C2Cl)=O)=O)CC(C)C)OC1=O)O

Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

soluble in DMSO, not soluble in water.

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Note: Some vendor mistakenly listed Name: MLN9708 /CAS#1201902-80-8 as Ixazomib.
MLN9708 is a prodrug of Ixazomib. MLN9708 is not the same as Ixazomib.

Ixazomib, also known as MLN-2238, it's CAS# is 1072833-77-2, please see our website:


1: Gupta N, Huh Y, Hutmacher MM, Ottinger S, Hui AM, Venkatakrishnan K. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemother Pharmacol. 2015 Jul 4. [Epub ahead of print] PubMed PMID: 26141494.

2: Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Morabito F, Gentili S. Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015 Jul 3:1-12. [Epub ahead of print] PubMed PMID: 26138345.

3: Reese SR, Wilson NA, Huang G, Redfield RR 3rd, Zhong W, Djamali A. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model. Transplantation. 2015 Apr 27. [Epub ahead of print] PubMed PMID: 25919767.

4: Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015;11(8):1153-68. doi: 10.2217/fon.15.9. PubMed PMID: 25832873.

5: Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs. 2015 Jun;33(3):652-63. doi: 10.1007/s10637-015-0230-x. Epub 2015 Mar 18. PubMed PMID: 25777468; PubMed Central PMCID: PMC4435632.

6: Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec;15(13):1503-12. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14. PubMed PMID: 25456369.

7: Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol. 2015 May;79(5):789-800. doi: 10.1111/bcp.12542. PubMed PMID: 25377318; PubMed Central PMCID: PMC4415715.

8: Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer J. 2014 Oct 17;4:e251. doi: 10.1038/bcj.2014.71. PubMed PMID: 25325301; PubMed Central PMCID: PMC4220649.

9: Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014. Review. PubMed PMID: 25302026; PubMed Central PMCID: PMC4189713.

10: Moreau P. Oral therapy for multiple myeloma: ixazomib arriving soon. Blood. 2014 Aug 14;124(7):986-7. doi: 10.1182/blood-2014-06-581611. PubMed PMID: 25124778; PubMed Central PMCID: PMC4133498.

11: Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. doi: 10.1182/blood-2014-01-548826. Epub 2014 Jun 11. PubMed PMID: 24920586.

12: Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014 Aug 14;124(7):1047-55. doi: 10.1182/blood-2014-01-548941. Epub 2014 Jun 5. PubMed PMID: 24904120; PubMed Central PMCID: PMC4468583.

13: Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S. (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J. 2013 Nov 29;3:e165. doi: 10.1038/bcj.2013.61. PubMed PMID: 24292417; PubMed Central PMCID: PMC3880444.